Telocytes are the physiological counterpart of inflammatory fibroid polyps and PDGFRA-mutant GISTs

Riccardo Ricci | Maria Cristina Giustiniani | Marco Gessi | Paola Lanza | Federica Castri | Alberto Biondi | Roberto Persiani | Fabio M. Vecchio | Mauro Risio

1Department of Pathology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “A. Gemelli”, Rome, Italy
2Department of Surgery, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “A. Gemelli”, Rome, Italy
3Department of Pathology, Emeritus, IRCCS Candiolo, Italy

Correspondence
Riccardo Ricci
Email: riccardo.ricci@unicatt.it

Funding information
Università Cattolica del Sacro Cuore, Grant/Award Number: 70200367

Abstract

PDGFRA mutations in the gastrointestinal (GI) tract can cause GI stromal tumour (GIST) and inflammatory fibroid polyp (IFP). Hitherto no cell type has been identified as a physiological counterpart of the latter, while interstitial Cajal cells (ICC) are considered the precursor of the former. However, ICC hyperplasia (ICCH), which strongly supports the ICC role in GIST pathogenesis, has been identified in germline KIT-mutant settings but not in PDGFRA-mutant ones, challenging the precursor role of ICC for PDGFRA-driven GISTs. Telocytes are a recently described interstitial cell type, CD34+/PDGFRA+. Formerly considered fibroblasts, they are found in many organs, including the GI tract where they are thought to be involved in neurotransmission. Alongside IFPs and gastric GISTs, GI wall “fibrosis” has been reported in germline PDGFRA-mutants. Taking the opportunity offered by its presence in a germline PDGFRA-mutant individual, we demonstrate that this lesion is sustained by hyperplastic telocytes, constituting the PDGFRA-mutant counterpart of germline KIT mutation-associated ICCH. Moreover, our findings support a pathogenetic relationship between telocyte hyperplasia and both IFPs and PDGFRA-mutant GISTs. We propose the term “telocytoma” for defining IFP, as it conveys both the pathogenetic (neoplastic) and histotypic (“telocytary”) essence of this tumour, unlike IFP, which rather evokes an inflammatory-hyperplastic lesion.

KEYWORDS
gastrointestinal stromal tumour, inflammatory fibroid polyp, interstitial cell of Cajal, PDGFRA-mutant syndrome, syndromic gastrointestinal stromal tumour, syndromic inflammatory fibroid polyp, telocyte, telocyte hyperplasia, telocytoma, tumour precursor

1 INTRODUCTION

Inflammatory fibroid polyps (IFPs) are benign, polypoid lesions usually centred in the submucosa of the gastrointestinal (GI) tract, with a predilection for gastric antrum. They consist of a proliferation of spindle, stellate or epithelioid mesenchymal cells harboured in a vascularized stroma, infiltrated by inflammatory cells (often with numerous eosinophils). Immunohistochemically, the lesional mesenchymal cells express CD34 and platelet-derived growth factor receptor alpha (PDGFRA). Most IFPs bear PDGFRA mutations. A subset of GI stromal tumours (GISTs), accounting for 6%-7% of the total, also harbours PDGFRA mutations, similar to...
IFPs. This GIST subgroup, which manifests a strong predilection for the stomach, is frequently at least partly epithelioid and, unlike other GISTs, is often negative or only faintly/patchy positive for CD117.

No physiological counterpart has hitherto been described for IFPs, although it has been suggested that they may develop from PDGFRA-positive mesenchymal cells found along the villus membrane in the small intestine. Conversely, GISTs as a whole are commonly considered to be related to interstitial cells of Cajal (ICC). Beyond the immunophenotype shared between most GISTs and ICCs (CD117+, DOG1+), the presence of ICC hyperplasia (ICCH) both in human germline KIT-mutant kindreds and in mice engineered to express KIT mutations found in human GISTs strongly supports a relationship between ICCs and GISTs. However, to date, no ICCH has been detected either in human germline PDGFRA-mutants or in mice generated for the conditional expression of mutant PDGFRA, arguing against a relationship between ICCs and PDGFRA-driven GISTs. Conversely, GI stromal cell hyperplasia has been described in these conditions, especially at submucosal level.

Telocytes (TCs) are a type of interstitial cell, formerly named interstitial Cajal-like cells, described in the connective tissue of several organs, including the GI tract. For a long time, they went unrecognized and were labelled simplistically as fibroblasts. In the GI tract, TCs are CD34+, PDGFRA+ and CD117-, and are thought to play a role in neurotransmission, possibly by spreading the low waves generated by ICCs. A relationship between TCs and GISTs (without genotypic distinction) or IFPs has been sometimes suggested, based on shared immunohistochemical markers and/or, in the former instance, to explain the occurrence of extragastrintestinal cases.

We previously published a kindred bearing a germline mutation (CC→TT at 1957-58) that led to a Leu for Pro substitution at 653 (P653L) in PDGFRA gene. The proband featured GI tumours encompassing GISTs, IFPs (including tumours previously described as “fibrous tumours”) and a lipoma, and an intramural diffuse stromal cell proliferation, heavily affecting the submucosa, in the stomach and proximal duodenum. We carried out a morphological and immunophenotypical investigation of the histotype of these stromal cells in order to establish their possible morphogenetic and/or pathogenetic relationship with synchronous IFPs and GISTs.

2 MATERIALS AND METHODS

2.1 Tissue specimens

The gastric tissues investigated were from the only member of a previously published germline PDGFRA-mutant kindred who featured a remarkably marked stromal proliferation of the gastroduodenal wall together with IFPs and GISTs. The procedures followed were in accordance with the ethical standards of the local institutional committee on human experimentation and with the Helsinki declaration of 1975, as revised in 1983. Informed written consent for this study was obtained from the patient.

2.2 Histology and immunohistochemistry

Sections from formalin-fixed, paraffin-embedded specimens were stained with haematoxylin/eosin. The following antibodies were employed: CD117 (DAKO, Glostrup, Denmark, rabbit polyclonal, 1:400), CD34 (Novocastra, Newcastle, UK, 1:50) and PDGFRA (sc-338) (Santa Cruz, Santa Cruz, CA, rabbit polyclonal, 1:400) (in all cases for 30 at room temperature). Antigen retrieval was performed for PDGFRA (10 minutes at 97°C, in 0.01 M citrate buffer, pH 6, PT link, DAKO). Specific preimmune sera or isotype-specific unrelated primary antibodies were used for the control stainings. The detection system consisted of DAKO visualization reagent (dextran polymer conjugated with horseradish peroxidase and goat anti-rabbit and antimouse immunoglobulins) with 3,3'- diaminobenzidine chromogen solution. Sections were counterstained with haematoxylin.

3 RESULTS

3.1 Histological characterization of GI wall diffuse stromal proliferation

A proliferation of stromal tissue involved the stomach wall (Figure 1A) and proximal duodenum. It started as two bands lining the inner and outer aspects of the submucosa. These showed a tendency to merge and ultimately completely obliterate this structure (Figure 1C). Higher magnification revealed spindle-to-polygonal shaped cells set in a variably collagenized background, often displaying thin cytoplasmic processes, at times extremely long, at times apparently interconnecting (Figure 1D). When involving muscular propria, they dissociated smooth muscle fascicles according to an interstitial pattern of growth (Figure 1F). These cells were diffusely and intensely positive for CD34 (Figure 1B and I) and PDGFRA (Figure 1E and G) but turned out to be CD 117 negative (Figure 1H).

Besides the interstitial PDGFRA-positive cells, CD34 IHC stained the endothelial lining of vessels, including the numerous capillaries present (Figure 1I). Conversely, CD117 revealed another population of cells with elongated cytoplasmic processes, not highlighted by PDGFRA IHC, either at the interface between fibrous tissue and smooth muscle fascicles or inside the latter, in close contact with smooth muscle cells; the only cell type stained in the fibrous intermuscular interstitium by CD117 IHC were mast cells (Figure 1H).

3.2 Relationship between GI wall diffuse stromal proliferation and IFP

Several typical IFPs were detected, histologically superimposable to their sporadic counterpart, being composed of an admixture of fibroblast-like CD34+ mesenchymal cells and inflammatory cells, often with numerous eosinophils, in a myxoid collagenous background. Interestingly, IFPs stemmed from the aforementioned diffuse stromal proliferation (Figure 2A and B) and a progressive loss of cytoplasmic processes in the constitutive cells was found at the interface of the two sectors, ultimately leading to the plump,
spindled/polygonal/epithelioid stromal cells typical of PFI (Figure 2A, C,E,F). PDGFRA positivity was maintained, albeit with an overall decreased intensity (Figure 2D and G).

### 3.3 | Relationship between GI wall diffuse stromal proliferation and GIST

Two gastric GISTs were present, whose histological features were indistinguishable from those of their sporadic PDGFRA-mutant counterpart, featuring epithelioid cytology and PDGFRA and CD117 (patchy-weak) positivity, as shown in Figure 3. Notably, near the gastric muscularis propria permeated by the previously described fibrous proliferation (Figure 3B) the GIST was characterized by a cytology that was relatively spindled (Figure 3E) compared to the overtly epithelioid type visible in the other parts of the tumour (Figure 3H). Moreover, unlike the nearby gastric wall, where both interstitial cells intensely positive for either PDGFRA or CD117 were present (Figure 3C-D), the intramural periphery of GIST was intensely positive for PDGFRA only, with slightly focal, weak CD117 staining (Figure 3F-G). A stronger, albeit patchy, CD117 positivity was present only towards the centre and in the subserosal portion of the GIST, accompanied by a persistent intense and diffuse PDGFRA reactivity (Figure 3I-J).
We herein report a detailed morphological and immunophenotypical analysis of the diffuse stromal proliferation described in the GI wall in PDGFRA-mutant syndrome and of its relationship with IFP and GIST, by exploiting the exceptional opportunity offered by its remarkable manifestation, together with the presence of these tumours, in an individual from a kindred previously published by the authors. As expected, germline PDGFRA mutations are able to originate multiple IFPs and GISTs. However, a third type of GI lesion, consisting of an intramural diffuse stromal proliferation variably referred to as “submucosal fibrous thickening,” “intestinal fibrosis,” “increased submucosal connective tissue,” “thickened submucosa” or “expanded submucosa,” has often been described in this genetic setting, both in humans and in mice. It consists of a CD34+ stromal proliferation, that variously involves the entire thickness of the GI tract, often heavily affecting the submucosa (Figure 1A-C). In a previous paper describing PDGFRA-mutant syndrome, we found this stromal proliferation remarkably evident in the stomach and duodenum of an individual, demonstrating that, in the submucosa, it often consisted of two thick bands running along its inner and outer limits; furthermore, its constitutive cells were positive not only for CD34, but also for PDGFRA, whereas both CD117 and DOG1 were negative. Here, besides confirming these characteristics, we show that these stromal cells often display long, slender cytoplasmic processes that sometimes appear to connect with each other (Figure 1D-G). The consistent detection of
these morphological features in cells positive at CD34 and at PDGFRA IHC (we did not perform a double immunostaining for CD34 and PDGFRA; this constitutes a limitation of our study) is coherent with the existence of a CD34/PDGFRA double-positive cell type clearly distinct from other cells of the interstitium that can express PDGFRA, that is mast cells, or CD34, that is endothelial cells. In particular, endothelial lining often encircles vascular lumens, a feature allowing its clear identification without need of CD31 immunostaining, a useful additional tool for identifying endothelial cells in questionable cases. In particular, endothelial lining often encircles vascular lumens, a feature allowing its clear identification without need of CD31 immunostaining, a useful additional tool for identifying endothelial cells in questionable cases. In particular, endothelial lining often encircles vascular lumens, a feature allowing its clear identification without need of CD31 immunostaining, a useful additional tool for identifying endothelial cells in questionable cases. In particular, endothelial lining often encircles vascular lumens, a feature allowing its clear identification without need of CD31 immunostaining, a useful additional tool for identifying endothelial cells in questionable cases. In particular, endothelial lining often encircles vascular lumens, a feature allowing its clear identification without need of CD31 immunostaining, a useful additional tool for identifying endothelial cells in questionable cases.

Thus, the stromal cells we describe display characteristics typical of TCs, both morphologically and immunophenotypically. In fact, TCs are characterized by a nucleated body (whose shape varies from small oval to triangular/polygonal or large round-to-oval, depending on the TCs' anatomical location) that branches out into extremely long and thin prolongations, called “telopodes”; moreover, CD34 and PDGFRA are currently considered the most reliable markers for their immunohistochemical identification. Additionally, the cells we describe are clearly distinguishable from ICCs because of both their immunophenotype and their compartmentalization. In fact, (i) they stain PDGFRA+ and CD117-, unlike ICCs, which display a reciprocal staining; (ii) they recapitulate the physiological intramural distribution of TCs within the GI wall; (iii) in particular, they are present in the submucosa, where ICCs are not found and, before completely obliterating it (Figure 1C), they form two thick bands along its inner and outer aspects (Figure 1A-B), that is exactly where the TCs physiologically form a monolayer; (iv) when in the muscularis propria, they are preferentially located within the interstitial “fibrosis,” whereas the CD117+ ICCs are found always in close contact with smooth muscle cells either at the interface between intermuscular stromal tissue and smooth muscle fascicles or within the latter (in keeping with intramuscular ICC-ICC-IM-, known to be intercalated between the intramural neurons and smooth myocytes) (Figure 1F-H). Of note, nerve endings are rarely observed in the proximity of TCs. On the grounds of all these findings, it is our opinion that the GI wall diffuse stromal proliferation typical of PDGFRA-mutant syndrome is sustained by hyperplastic TCs, constituting the “PDGFRA-driven counterpart” of ICCH.
typical of germline KIT mutations. Of note, this finding confutes the histotype concealed by two of the terms previously used for defining the referred stromal proliferation, that is, "submucosal fibrous thickening" and "intestinal fibrosis". In fact, TCs are decreased in conditions determining a genuine fibrosis of GI wall such as Crohn’s disease and ulcerative colitis.28,31

We went on to ascertain whether it was possible to detect morphological and/or immunophenotypical clues potentially linking TC hyperplasia with IFP or GIST in PDGFRA-mutant syndrome.

With regard to IFPs, we have already described examples stemming from the “submucosal thickening” found in an individual affected by PDGFRA-mutant syndrome.9 Herein, we show also that there appears to be a gradual cytologic progression from TCs constituting the aforementioned thickening to stromal cells forming IFP, with a gradual loss of both slender cytoplasmic processes and relative cell elongation, accompanied by the acquisition of a relatively plumper morphology in the presence of a persisting, although overall less intense, positivity for PDGFRA (Figure 2C-G). We therefore conclude that the TC hyperplasia forming the submucosal thickening characteristic of PDGFRA-mutant syndrome, studied in this investigation, is pathogenetically related to IFP. Consequently, by analogy with what has been inferred from ICCH in germline KIT-mutant settings regarding the relationship between ICC and KIT-mutant GIST, TC can be considered the physiological counterpart of IFP. Consistently, it is noticeable that a subtype of TC, differing from the other GI TCs because of its lack of CD34 expression, has been described in the axes of intestinal villi both in humans and mice27 and that intestinal IFPs, unlike gastric ones, are often CD34-.1,2

Accumulating evidence has demonstrated that GISTs encompass a group of heterogeneous stromal tumours which, despite often sharing some features among overall GI location, spindle or epithelioid cytology, relatively mild atypia, low mitotic activity and immunoreactivity for DOG1 and CD117, nevertheless differ in molecular pathogenesis and, consequently, in anatomical distribution along GI tract. usual cytoarchitectural characters, immunophenotype, prognosis and drug sensitivity.3 Concerning the minority subgroup of PDGFRA-mutant GISTs and their physiological counterpart, apart from the abovementioned lack of ICCH in PDGFRA-mutant syndrome, it is worth noting that, unlike most other GISTs, these tumours are often CD117− or only weakly and patchy CD117+.3 Noticeably, TCs are CD117− in the GI tract, but may express this marker elsewhere.24,29 Moreover, TCs are present within the muscularis propria (ie, the GI layer originating GISTs) both physiologically and, with hyperplastic characteristics, in PDGFRA-mutant syndrome (Figures 1 and 3). Under these circumstances, it is remarkable that an analysis of the transition between the gastric muscular wall and GIST in this latter condition demonstrates that (i) hyperplastic PDGFRA− CD117− TCs are present in the muscularis propria close to the GISTs, along with physiological PDGFRA−CD117+ ICC-IM (Figure 3A-D); (ii) the periphery of the GIST close to muscularis propria shows a relatively spindled cytology together with an intense PDGFRA positivity but only a weak and focal CD117 staining, characteristics which, in relation to the two types of neighbouring interstitial cells, globally recall TCs rather than ICCs (Figure 3A,E-G); (iii) a wholly epithelioid cytology is reached, sometimes flanked by a relatively strong CD117 immunoreactivity, only at a certain distance from muscularis propria (where PDGFRA positivity is nevertheless preserved) (Figure 3A,H-J). Considering the hyperplastic condition of TCs in PDGFRA-mutant syndrome, we believe that this evidence supports a relationship of TCs also with PDGFRA-mutant GISTs.

Differences in TC features, possibly concealing different TC subpopulations and varying with both GI segment and GI wall layer,24 together with possible site-specific differences in gene expression,32 could explain how TCs as a whole can originate diverse tumour types, and why, unlike IFPs, PDGFRA-mutant GISTs show a strong (albeit not entirely exclusive) gastric predilection.33,34

Our results are based on the study of the only individual featuring a prominent diffuse stromal proliferation of GI wall from a PDGFRA-mutant kindred we previously investigated.9 In absolute terms, this constitutes a limitation to the significance of our conclusions. However, it must be considered that germline PDGFRA mutations are an exceedingly rare event in humans, with only five to six examples (considering kindreds or single individuals) reported in the literature27,28; on top of that, the presence of GI diffuse stromal proliferation together with IFPs and/or GISTs, that is the ideal setting for investigating the relationship between these latter tumours and TCs, has been reported in a fraction only of mutants (in particular, with regard to the kindred we previously published, only in the proband, that is member II-2).5,9 The study of sporadic IFPs and PDGFRA-mutant GISTs is probably of limited utility for defining a possible link between these tumours and TCs as, under these circumstances, only the fully developed neoplastic morphological and immunophenotypical characters of the former tumours are observable, features which could be deemed not to be specific enough in terms of cell lineage in the absence of any type of transition with respect to physiological TCs.

In conclusion, our results support TCs as the physiological counterpart of both IFPs and PDGFRA-mutant GISTs, possibly pathogenetically related to both of these tumour types. Furthermore, on the basis of our results we herein propose “telocytoma” as a more appropriate term than IFP for defining the lesion formerly referred to as “Vanek’s tumour.” In fact, compared to the misleading “inflammatory fibroid polyp” definition that evokes an aspecific inflammatory fibrous lesion, “telocytoma” conveys both the correct pathogenetic (that is neoplastic) and histotypic (that is “telocytary”) essence of this lesion (semantically reiterating the changeover from “colonic fibroblastic polyp” to “colonic perineurioma”).35 Further studies are warranted to further shed light on this fascinating topic.

ACKNOWLEDGEMENTS

We are grateful for our patient’s generosity in participating in this research. This work was supported by a grant from the Università Cattolica del Sacro Cuore, Italy (Linea D1 Grant number 70200367 to RR). RR designed the research study; RR, MCG, MG, PL, FC, AB, RP, FMV and MR performed the research and analysed the data; RR and MR wrote the manuscript; all the authors critically revised the manuscript and approved it.
REFERENCES

1. Schildhaus HU, Cavlar T, Binot E, et al. Inflammatory fibroid polyps harbour mutations in the platelet-derived growth factor receptor alpha (PDGFRα) gene. J Pathol. 2008;216:178-182.

2. Lasota J, Wang ZF, Sobin LH, Miettinen M. Gain-of-function PDGFRα mutations, earlier reported in gastrointestinal stromal tumors, are common in small intestinal inflammatory fibroid polyps. A study of 60 cases. Mod Pathol. 2009;22:1049-1056.

3. Ricci R, Del Tos AP, Rindi G. GISTogram: a graphic presentation of the growing GIST complexity. Virchows Arch. 2013;463:481-487.

4. Martini M, Santoro L, Ferrari P, et al. Inflammatory fibroid polyp of the gallbladder bearing a platelet-derived growth factor receptor alpha mutation. Arch Pathol Lab Med. 2013;137:721-724.

5. Corless CL. Gastrointestinal stromal tumors: what do we know now? Mod Pathol. 2014;27(Suppl 1):S1-S16.

6. Rubin BP, Antonescu CR, Scott-Browne JP, et al. A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res. 2005;65:6631-6639.

7. Ricci R. Syndromic gastrointestinal stromal tumors. Hered Cancer Clin Pract. 2016;14:15.

8. Manley PN, Abu-Abed S, Kirsch R, et al. Familial PDGFRα mutation-syndrome: somatic and gastrointestinal phenotype. Hum Pathol. 2016;76:52-57.

9. Ricci R, Martini M, Cenci T, et al. PDGFRα-mutant syndrome. Mod Pathol. 2015;28:954-964.

10. Olson LE, Soriano P. Increased PDGFRα activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell. 2009;16:303-313.

11. Popescu LM, Faussone-Pellegrini MS. TELOCYTES - a case of serendipidity; the winding way from Interstitial Cells of Cajal (ICC), via Intestinal Cajal-Like Cells (ICLC) to TELOCYTES. J Cell Mol Med. 2010;14:729-740.

12. Hinescu ME, Popescu LM. Intestinal Cajal-like cells (ICLC) in human atrial myocardium. J Cell Mol Med. 2005;9:972-975.

13. Ciontea SM, Radu E, Regalia T, et al. C-kit immunopositive interstitial cells (Cajal-type) in human myometrium. J Cell Mol Med. 2005;9:407-420.

14. Popescu LM, Ciontea SM, Cretoiu D, et al. Novel type of interstitial cell (Cajal-like) in human fallopian tube. J Cell Mol Med. 2005;9:479-523.

15. Gherghiceanu M, Popescu LM. Intestinal Cajal-like cells (ICLC) in human resting mammary gland stroma. Transmission electron microscope (TEM) identification. J Cell Mol Med. 2005;9:893-910.

16. Hinescu ME, Ardeleanu C, Gherghiceanu M, Popescu LM. Intestinal Cajal-like cells in human gallbladder. J Mol Histol. 2007;38:275-284.

17. Hinescu ME, Popescu LM, Gherghiceanu M, Faussone-Pellegrini MS. Intestinal Cajal-like cells in rat mesentery: an ultrastructural and immunohistochemical approach. J Cell Mol Med. 2008;12:260-270.

18. Pieri L, Vannucchi MG, Faussone-Pellegrini MS. Histochemical and ultrastructural characteristics of an interstitial cell type different from ICC and resident in the muscle coat of human gut. J Cell Mol Med. 2008;12:1944-1955.

19. Popescu LM, Manole CG, Gherghiceanu M, et al. Telocytes in human epicardium. J Cell Mol Med. 2010;14:2085-2093.

20. Suciu L, Popescu LM, Gherghiceanu M, et al. Telocytes in human term placenta: morphology and phenotype. Cells Tissues Organs. 2010;192:325-339.

21. Hinescu ME, Gherghiceanu M, Suciu L, Popescu LM. Telocytes in pleura: two- and three-dimensional imaging by transmission electron microscopy. Cell Tissue Res. 2011;343:389-397.

22. Cretoiu D, Cretoiu SM, Simionescu AA, Popescu LM. Telocytes, a distinct type of cell among the stromal cells present in the lamina propria of jejenum. Histol Histopathol. 2012;27:1067-1078.

23. Chen X, Zheng Y, Manole CG, et al. Telocytes in human oesophagus. J Cell Mol Med. 2013;17:1506-1512.

24. Vannucchi MG, Traini C, Manetti M, et al. Telocytes express PDGFRα in the human gastrointestinal tract. J Cell Mol Med. 2013;17:1099-1108.

25. Ardeleanu C, Bussolati G. Telocytes are the common cell of origin of both PEComas and GISTs: an evidence-supported hypothesis. J Cell Mol Med. 2011;15:2569-2574.

26. Carney JA, Stratakis CA. Stromal, fibrous, and fatty gastrointestinal tumors in a patient with a PDGFRα gene mutation. Am J Surg Pathol. 2008;32:1412-1420.

27. Vannucchi MG, Traini C. Interstitial cells of Cajal and telocytes in the gut: twins, related or simply neighbor cells? Biomol Concepts. 2016;7:93-102.

28. Manetti M, Rosa I, Messerini L, Ibba-Manneschi L. Telocytes are reduced during fibrotic remodelling of the colonic wall in ulcerative colitis. J Cell Mol Med. 2015;19:62-73.

29. Ibba-Manneschi L, Rosa I, Manetti M. Telocyte implications in human pathology: An overview. Semin Cell Dev Biol. 2016;55:62-69.

30. Streutker CJ, Huizinga JD, Driman DK, Riddell RH. Interstitial cells of Cajal in health and disease. Part I: normal ICC structure and function with associated motility disorders. Histopathology. 2007;50:176-189.

31. Milia AF, Ruffo M, Manetti M, et al. Telocytes in Crohn’s disease. J Cell Mol Med. 2013;17:1525-1536.

32. Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res. 2004;10:3282-3290.

33. Lasota J, Danuska-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRα mutations represent gastric tumors of low or no malignant potential. Lab Invest. 2004;84:874-883.

34. Corless CL, Schroeder A, Griffith D, et al. PDGFRα mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:5357-5364.

35. Groisman GM, Polak-Charcon S. Fibroblastic polyp of the colon and colonic perineurioma: 2 names for a single entity? Am J Surg Pathol. 2008;32:1088-1094.

How to cite this article: Ricci R, Giustiniani MC, Gessi M, et al. Telocytes are the physiological counterpart of inflammatory fibroid polyps and PDGFRα-mutant GISTs. J Cell Mol Med. 2018;22:4856-4862. https://doi.org/10.1111/jcmm.13748